Synthesis of Isotope Labeled Cholesterol Derivatives as Diagnostic Agents

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes the synthesis and use of isotope (radio) labeled cholesterol derivatives, including compounds containing isotopes such as 18F, 131I, 124I, or deuterium. These derivatives have enhanced stability and can act as diagnostic agents or treatment agents for infectious diseases (like pneumonia or septic cardiomyopathy) and cholesterol-related conditions (e.g., Smith-Lemli-Opitz syndrome). The labeled compounds can be detected using imaging techniques such as PET/CT. Furthermore, they may be integrated into pharmaceutical and nanomedicine formulations, providing both therapeutic and diagnostic (theranostic) benefits.

Use CasesContent extracted from patent full text and abstract with AI.

• Detection and monitoring of infectious diseases using PET/CT imaging with radiolabeled cholesterol derivatives.
• Treatment of infectious diseases such as pneumonia or septic cardiomyopathy with improved drug formulations.
• Therapeutic management of cholesterol-related disorders, including genetic diseases like Smith-Lemli-Opitz syndrome.
• Integration as functional components in nanomedicine drug delivery systems for personalized or targeted therapy, especially in tumor treatments.
• Real-time drug monitoring and individualized dosage adjustment in patients receiving cholesterol-containing nanoformulations.

BenefitsContent extracted from patent full text and abstract with AI.

• Improved pharmacokinetic and pharmacodynamic properties compared to existing cholesterol-based compounds.
• Greater metabolic stability for prolonged activity in vivo.
• Dual diagnostic and therapeutic potential (theranostics), enabling both treatment and non-invasive monitoring.
• Potential to enhance resistance of host cells against bacterial toxins and virulence factors.
• Flexible compatibility with existing and new pharmaceutical nanoformulations, allowing for broad application in both diagnostics and treatment.
• Personalized medicine capabilities due to chemical versatility and compatibility with imaging modalities.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention concerns synthesis of isotope labeled cholesterol derivatives as diagnostic agents. The isotopes are radio labeled and/or labelled isotopes, namely 18F, and/or 131I, and/or 124I , and/or deuterium. In addition, the invention concerns the use of radiolabeled cholesterol derivatives as well as their physiologically tolerated salts for the preparation of pharmaceutical drugs for the treatment of infectious diseases, particularly pneumonia or septic cardiomyopathy, but also other diseases associated with decreased cholesterol levels (hypercholesterinemia), e.g. Smith-Lemli-Opitz syndrome. In a further addition, the invention discloses pharmaceutical formulation containing radiolabeled cholesterol derivatives as well as their physiologically tolerated salts for the treatment of infectious diseases, particularly pneumonia or septic cardiomyopathy, but also other diseases associated with decreased cholesterol levels (hypercholesterinemia), e.g. Smith-Lemli-Opitz syndrome.